• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism.

作者信息

Jensen Morten Krogh, Riisbro Rikke, Holten-Andersen Mads N, Brown Peter de Nully, Junker Peter, Brünner Nils, Hasselbalch Hans C

机构信息

Department of Haematology L, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.

出版信息

Eur J Haematol. 2003 Oct;71(4):276-82. doi: 10.1034/j.1600-0609.2003.00134.x.

DOI:10.1034/j.1600-0609.2003.00134.x
PMID:12950237
Abstract

Extracellular proteolytic enzymes of the urokinase-type plasminogen activator (uPA) system and the family of metalloproteinases (MMPs) catalyse the matrix degradation and remodelling processes characteristic of invasive malignant disorders. In a cohort of 50 patients with chronic myeloproliferative disorders (MPD) serum markers for collagen metabolism were compared to plasma levels of enzymes of the uPA and MMP system. Serum aminoterminal propeptide of type III procollagen (S-PIIINP) (P < 0.0001) concentration was significantly higher in the patients (median 3.7 micro g/L vs. 2.5 micro g/L) compared with controls. In a subgroup analysis comprising patients with myelofibrosis (MF), polycythaemia vera (PV) and essential thrombocythaemia (ET), respectively, S-PIIINP levels differed significantly with the highest values found in patients with MF (MF vs. PV vs. ET; P = 0.0027). Serum concentration of carboxyterminal telopeptide of type I collagen (S-ICTP) (P = 0.0006), reflecting type I collagen degradation, was significantly higher in patients compared with controls (median 4.0 micro g/L vs. 2.7 micro g/L). When comparing S-ICTP measurements between patient subgroups and controls there were only significantly higher values among MF and PV patients (MF vs. controls; P < 0.0001, PV vs. controls; P = 0.0016). A significant correlation between the marker for collagen synthesis (S-PIIINP) and degradation (S-ICTP) (r = 0.59; P < 0.0001) was demonstrated. A correlation analysis between serum markers for bone marrow remodelling processes (S-PIIINP, S-ICTP and S-hyaluronan) and plasma-soluble urokinase plasminogen receptor (suPAR) disclosed a significant relationship between suPAR and S-PIIINP (r = 0.48; P = 0.0009), S-hyaluronan (r = 0.56; P < 0.0001) and S-ICTP (r = 0.47; P = 0.0013), respectively. Plasma levels of MMP-2 and -9 were not correlated to serum markers for collagen metabolism. These findings suggest that enzymes of the uPA system might participate in the bone marrow remodelling processes characteristic of MPD.

摘要

相似文献

1
Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism.
Eur J Haematol. 2003 Oct;71(4):276-82. doi: 10.1034/j.1600-0609.2003.00134.x.
2
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.特发性骨髓纤维化或真性红细胞增多症患者血浆中可溶性尿激酶型纤溶酶原激活物受体升高。
Eur J Haematol. 2002 Jul;69(1):43-9. doi: 10.1034/j.1600-0609.2002.01732.x.
3
Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders.
Eur J Haematol. 2003 Nov;71(5):377-84. doi: 10.1034/j.1600-0609.2003.00096.x.
4
Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan.
Am J Hematol. 1994 Jul;46(3):173-8. doi: 10.1002/ajh.2830460303.
5
[The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].慢性乙型肝炎后不同阶段肝硬化患者血浆中尿激酶型纤溶酶原激活物、尿激酶型纤溶酶原激活物受体及纤溶酶原激活物抑制剂-1的水平
Zhonghua Gan Zang Bing Za Zhi. 2004 Feb;12(2):82-4.
6
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.通过测定卵巢癌FIGO II和III期患者血清中的尿激酶型纤溶酶原激活剂(uPA)和可溶性尿激酶型纤溶酶原激活剂受体(suPAR)来监测铂/紫杉醇化疗方案的化疗成功率。
Bosn J Basic Med Sci. 2007 May;7(2):111-6. doi: 10.17305/bjbms.2007.3063.
7
Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.急性髓系白血病患者中的尿激酶型纤溶酶原激活物受体与可溶性基质金属蛋白酶-9:与疾病侵袭的可能关系
Hematology. 2003 Dec;8(6):385-91. doi: 10.1080/10245330310001621323.
8
Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.炎症性风湿性疾病患者血浆中的可溶性尿激酶型纤溶酶原激活物受体:类风湿关节炎患者浓度升高。
Ann Rheum Dis. 1999 Aug;58(8):488-92. doi: 10.1136/ard.58.8.488.
9
Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.与明胶酶-B(基质金属蛋白酶-9)相关的尿激酶型纤溶酶原激活剂、受体及抑制剂在膝关节痛风性关节炎的炎症中起作用。
J Rheumatol. 2006 Feb;33(2):311-7.
10
[Levels of procollagen type III n-terminal peptide (PIIINP) in serum of patients with myeloproliferative syndrome (mps)].[骨髓增殖综合征(MPS)患者血清中III型前胶原N端肽(PIIINP)水平]
Pol Arch Med Wewn. 1998 Jan;99(1):24-9.

引用本文的文献

1
Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.重新审视循环细胞外基质片段作为骨髓纤维化及相关肿瘤的疾病标志物
Cancers (Basel). 2023 Aug 29;15(17):4323. doi: 10.3390/cancers15174323.
2
Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers.骨髓纤维化患者的骨几何形态、骨密度和微观结构:一项使用双能X线吸收法(DXA)、高分辨率外周定量CT(HR-pQCT)和骨转换标志物的横断面研究。
Int J Hematol. 2015 Jul;102(1):67-75. doi: 10.1007/s12185-015-1803-3. Epub 2015 May 5.
3
JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells.
JAK2-V617F诱导的丝裂原活化蛋白激酶(MAPK)活性受磷脂酰肌醇-3激酶(PI3K)调控,并与PI3K协同作用于JAK2-V617F阳性细胞的增殖。
JAKSTAT. 2013 Jul 1;2(3):e24574. doi: 10.4161/jkst.24574. Epub 2013 Apr 8.
4
Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status.慢性特发性骨髓纤维化中胶原酶表达异常与疾病分期相关,但与JAK2突变状态无关。
Am J Pathol. 2006 Aug;169(2):471-81. doi: 10.2353/ajpath.2006.060110.